1. Caldolor's J-code J1741 is now linked to a reimbursement price. 2. Caldolor serves as a non-opioid pain management option amid the opioid crisis. 3. Healthcare providers are encouraged to update billing processes for Caldolor. 4. This change improves access to non-opioid treatments for pain management. 5. Cumberland Pharmaceuticals emphasizes commitment to reducing opioid exposure.
FAQ
Why Bullish?
Linking Caldolor to a reimbursement price may increase adoption by healthcare providers, driving sales. Historical examples show reimbursement updates generally lead to increased market penetration in pharmaceuticals.
How important is it?
The change is crucial for its market position, particularly as non-opioid demand rises.
Why Short Term?
Immediate increases in utilization are expected as providers adapt billing processes. A precedent exists where similar updates had quick sales responses.
Cumberland Pharmaceuticals Announces J-Code for Caldolor® Injection Linked to Reimbursement
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has made a significant announcement regarding its product, Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated with a reimbursement price, providing a non-opioid option for healthcare providers managing pain and fever.
Addressing the Opioid Crisis with Non-Opioid Alternatives
As the opioid crisis continues to affect the nation, healthcare providers are increasingly turning to non-opioid alternatives like Caldolor. With the reimbursement price now linked to J1741, providers will have access to a CMS-covered option, enabling them to align treatment strategies with opioid-sparing initiatives. This move is critical for supporting safer pain management strategies for patients.
- Product: Caldolor® (ibuprofen) Injection
- J-Code: J1741 – Injection, ibuprofen, 100 mg
- Status: Now associated with reimbursement price
Reimbursement Update Benefits Healthcare Providers
A.J. Kazimi, CEO of Cumberland Pharmaceuticals, expressed his thoughts on this development: "With Caldolor now linked to an established reimbursement price, healthcare providers have a reimbursable non-opioid alternative to help address pain management." This update not only supports clinicians in making appropriate decisions but also contributes to efforts aimed at minimizing opioid exposure.
Providers are encouraged to update their internal systems, billing teams, and reimbursement processes in light of this change. For further assistance regarding coding, coverage, or payment inquiries, Cumberland's representatives are available for support.
Overview of Caldolor® (Ibuprofen) Injection
Caldolor is indicated for managing mild to moderate pain and for use as an adjunct to opioid analgesics in moderate to severe pain, along with reducing fever. It holds the distinction of being the first FDA-approved intravenous therapy for treating fever. However, Caldolor is contraindicated for patients with known hypersensitivity to ibuprofen or other NSAIDs, and for those who have experienced allergic reactions to aspirin or similar medications.
For complete prescribing and safety information, including boxed warnings, visit www.caldolor.com.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company based in Tennessee, dedicated to developing and commercializing products that enhance patient care. Their portfolio includes FDA-approved products targeting various market segments, such as:
- Acetadote® (acetylcysteine) injection for acetaminophen poisoning
- Caldolor® (ibuprofen) injection for pain and fever management
- Kristalose® (lactulose) oral for treating constipation
- Sancuso® (granisetron) transdermal for preventing nausea and vomiting in chemotherapy patients
- Vaprisol® (conivaptan) injection for raising serum sodium levels
- Vibativ® (telavancin) injection for serious bacterial infections
- Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) oral for H. pylori infection
Future Clinical Programs
The company is also engaged in multiple Phase II clinical programs assessing its ifetroban product candidate for conditions such as cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis.
Forward-Looking Statements
This announcement contains forward-looking statements subject to risks that may differ from actual outcomes. Factors such as market conditions, competition, and regulatory compliance can significantly impact Cumberland's operational results. Readers are advised to review the Company's recent Form 10-K and subsequent 10-Q filings for more detailed information.